INK cells after chemoradiation for small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a special immune cell called iNK cells after standard chemoradiation can help keep small cell lung cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have small cell lung cancer that is locally advanced or has spread, and cannot be removed by surgery.
- You must be in generally good health (able to do daily activities without help).
- You must have a life expectancy of at least 3 months.
- You must not have serious heart, kidney, liver, or lung problems.
- You must not have active hepatitis, HIV, or other serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding special immune cells (iNKT cells and CD8+ T cells) given by IV infusion can help treat advanced cancers. It mainly looks at safety first, and also checks whether the treatment can shrink or control cancer.
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
This trial tests a new type of immune cell therapy called iNK (natural killer cells) for people with solid tumors that have come back or spread. It aims to see if the treatment is safe and can help shrink tumors.
This trial tests adding natural killer (NK) cell therapy to standard chemo and immunotherapy before surgery for stage IB to IIIA non-small cell lung cancer that can be removed. It aims to see if this combination helps shrink tumors and improve outcomes.
This trial is testing a new type of immune cell therapy called PANK-003, given alongside standard chemotherapy after surgery for stage IIIA non-small cell lung cancer (NSCLC). It aims to see if this combination can help prevent the cancer from coming back.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.